Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 15NIH 9NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 9Other hematologic neoplasm 8Sarcoma 5Plasma cell 2Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 48Bortezomib 22Lenalidomide 20Cyclophosphamide 20daratumumab 18Calcium Dobesilate 15Melphalan 13Thalidomide 12carfilzomib 9pomalidomide 7Prednisone 7dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6isatuximab 5Filgrastim 5Vincristine 4Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2belantamab mafodotin 2Steroids 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × sargramostim × Plasma cell × Clear all
NCT00014508 2023-06-22

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Eastern Cooperative Oncology Group

Phase 2 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00040937 2016-12-08

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡